Related Experiment Video

Updated: Mar 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis

Tamir Shragai1,2, Muhammad Ganayem3, Yael C Cohen3,4

  • 1Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. tamirsh@tlvmc.gov.il.

Annals of Hematology
|March 12, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Light-chain amyloidosisPlasma cell disordersRelapse/refractory amyloidosisT-cell engagers

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Related Experiment Videos

Last Updated: Mar 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K

Articles linked to this work by shared authors, journal, and citation graph.

Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study.

Haematologica·2026

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.

Nature genetics·2026

Free Light Chain Monomer-Dimer Pattern Analysis as Non-Invasive Tool in Predicting MGUS and SMM Progression.

Cancers·2026

Exploring variables leading to major postmarketing label changes in leading regulatory authorities: a retrospective cohort study in Israel.

BMJ open·2026

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.

Neurology(R) neuroimmunology & neuroinflammation·2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.

Annals of hematology·2026

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

Annals of hematology·2026

Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.

Annals of hematology·2026

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.

Annals of hematology·2026

Defining and managing high-risk acute myeloid leukemia (AML) in 2026.

Annals of hematology·2026

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma.

Annals of hematology·2026

Large-Bore Aspiration Thrombectomy for Recurrent Iliofemoral DVT in Congenital IVC Interruption With Azygous Continuation.

JACC. Case reports·2026

Healthy bone marrow transplantation into hypertriglyceridemic rats improves cardiac reparative fibrosis post-myocardial infarction.

Cardiovascular research·2026

Exploring antibody-antigen binding affinity using degree-based topological indices: a graph-theoretical approach.

Frontiers in chemistry·2026

Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy in an advanced disease stage: A case report.

Experimental and therapeutic medicine·2026

Soluble CTLA-4 as a context-dependent immune checkpoint: biology, biomarker potential, and therapeutic implications.

Frontiers in immunology·2026

Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A.

Blood vessels, thrombosis & hemostasis·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us